Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × epothilone B × Clear all

Phase

Status

Sponsor Class

INDUSTRY 12 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1 Neoplasm Metastasis 1 Meningeal Carcinomatosis 1 Hormone Refractory Prostate Cancer 1 Head and Neck Neoplasms 1 Glioblastoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Surveys and Questionnaires 93 Exercise 84 Blood Specimen Collection 75 Radiotherapy 59 Gemcitabine 49 Standard of Care 48 Bevacizumab 48 Cisplatin 47 Carboplatin 43 Dexamethasone 42 Capecitabine 41 Paclitaxel 39 Cyclophosphamide 39 Interviews as Topic 38 pembrolizumab 37 Docetaxel 37 Oxaliplatin 34 Methods 33 Magnetic Resonance Spectroscopy 32 Irinotecan 32 Fluorouracil 32 Therapeutics 27 Radiosurgery 25 Nivolumab 25 Drug Therapy 25 Educational Status 23 Leucovorin 20 Surgical Procedures, Operative 19 Everolimus 19 Erlotinib Hydrochloride 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00496600 2012-06-14

Phase I Study of Patupilone and RAD001

Rutgers, The State University of New Jersey

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡